NCT04104399View on ClinicalTrials.gov

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

January 28, 2022

Study Completion Date

March 30, 2022

Conditions
Migraine
Interventions
DRUG

XC101-D13H

XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules

DRUG

Placebo

Placebo supplied as matching capsules

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Xoc Pharmaceuticals

INDUSTRY

NCT04104399 - Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter